Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

9 Meters Biopharma, Inc. (NMTR)

1.3471   0.037 (2.83%) 03-22 12:54
Open: 1.32 Pre. Close: 1.31
High: 1.36 Low: 1.3
Volume: 20,143 Market Cap: 19(M)

Technical analysis

as of: 2023-03-22 12:48:49 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.22     One year: 2.66
Support: Support1: 1.28    Support2: 1.07
Resistance: Resistance1: 1.9    Resistance2: 2.27
Pivot: 1.48
Moving Average: MA(5): 1.34     MA(20): 1.54
MA(100): 1.86     MA(250): 4.75
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 5.6     %D(3): 6.9
RSI: RSI(14): 33.3
52-week: High: 13.19  Low: 0.22
Average Vol(K): 3-Month: 111 (K)  10-Days: 95 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NMTR ] has closed above bottom band by 20.7%. Bollinger Bands are 45.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.36 - 1.37 1.37 - 1.38
Low: 1.28 - 1.29 1.29 - 1.3
Close: 1.29 - 1.31 1.31 - 1.33

Company Description

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Headline News

Wed, 15 Mar 2023
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Yahoo Finance

Tue, 07 Mar 2023
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual ... - Digital Journal

Tue, 14 Feb 2023
Citigroup Initiates Coverage of 9 Meters Biopharma (NMTR) with ... - Nasdaq

Tue, 31 Jan 2023
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor ... - AccessWire

Wed, 04 Jan 2023
How Will the Market React to 9 Meters Biopharma Inc (NMTR) Stock Getting a Bullish Rating - InvestorsObserver

Mon, 17 Oct 2022
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 13 (M)
Shares Float 12 (M)
% Held by Insiders 1.2 (%)
% Held by Institutions 19.1 (%)
Shares Short 512 (K)
Shares Short P.Month 380 (K)

Stock Financials

EPS -0.15
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.18
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -51.2
Return on Equity (ttm) -132
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.12
Qtrly Earnings Growth 0
Operating Cash Flow -35 (M)
Levered Free Cash Flow -18 (M)

Stock Valuations

PE Ratio -9.02
PEG Ratio 0
Price to Book value 6.97
Price to Sales 0
Price to Cash Flow -0.49

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.